{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:33:55Z","timestamp":1794335635325,"version":"4.9.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"38","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.vaccine.2019.07.103","type":"journal-article","created":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T07:53:17Z","timestamp":1565596397000},"page":"5708-5716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague"],"prefix":"10.1016","volume":"37","author":[{"given":"William","family":"Bowen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4375-9004","authenticated-orcid":false,"given":"Lalit","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda R.","family":"Pulsifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esma S.","family":"Yolcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1505-5429","authenticated-orcid":false,"given":"Matthew B.","family":"Lawrenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1657-9470","authenticated-orcid":false,"given":"Haval","family":"Shirwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2019.07.103_b0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/01.inf.0000106918.18570.dd","article-title":"Plague","volume":"23","author":"Dennis","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.vaccine.2019.07.103_b0010","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.tim.2015.11.008","article-title":"Pneumonic plague: the darker side of Yersinia pestis","volume":"24","author":"Pechous","year":"2016","journal-title":"Trends Microbiol"},{"issue":"9568","key":"10.1016\/j.vaccine.2019.07.103_b0015","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0140-6736(07)60566-2","article-title":"Plague","volume":"369","author":"Prentice","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.07.103_b0020","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3389\/fimmu.2016.00602","article-title":"Plague vaccine development: current research and future trends","volume":"7","author":"Verma","year":"2016","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2019.07.103_b0025","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jme\/tjv128","article-title":"The Role of early-phase transmission in the spread of Yersinia pestis","volume":"52","author":"Eisen","year":"2015","journal-title":"J Med Entomol"},{"issue":"7","key":"10.1016\/j.vaccine.2019.07.103_b0030","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1128\/IAI.01296-09","article-title":"Milestones in progression of primary pneumonic plague in cynomolgus macaques","volume":"78","author":"Koster","year":"2010","journal-title":"Infect Immun"},{"issue":"8","key":"10.1016\/j.vaccine.2019.07.103_b0035","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1073\/pnas.1112729109","article-title":"Pulmonary infection by Yersinia pestis rapidly establishes a permissive environment for microbial proliferation","volume":"109","author":"Price","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.vaccine.2019.07.103_b0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000309","article-title":"Multiple antimicrobial resistance in plague: an emerging public health risk","volume":"2","author":"Welch","year":"2007","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.vaccine.2019.07.103_b0045","doi-asserted-by":"crossref","first-page":"415","DOI":"10.20506\/rst.36.2.2662","article-title":"A brief history of biological weapons programmes and the use of animal pathogens as biological warfare agents","volume":"36","author":"Zilinskas","year":"2017","journal-title":"Rev Sci Tech"},{"issue":"16","key":"10.1016\/j.vaccine.2019.07.103_b0050","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/0264-410X(95)00090-N","article-title":"A comparison of Plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model","volume":"13","author":"Russell","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.103_b0055","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/129.Supplement_1.S13","article-title":"Plague immunization. I. Past and present trends","volume":"129","author":"Meyer","year":"1974","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2019.07.103_b0060","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1517\/14712598.4.6.965","article-title":"Yersinia pestis (plague) vaccines","volume":"4","author":"Titball","year":"2004","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"10.1016\/j.vaccine.2019.07.103_b0065","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1586\/erv.13.42","article-title":"Live-attenuated Yersinia pestis vaccines","volume":"12","author":"Wang","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2019.07.103_b0070","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0928-8244(03)00170-6","article-title":"Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles","volume":"38","author":"Sabhnani","year":"2003","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"16","key":"10.1016\/j.vaccine.2019.07.103_b0075","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1016\/j.vaccine.2007.01.071","article-title":"Development of a recombinant vaccine against aerosolized plague","volume":"25","author":"Morris","year":"2007","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2019.07.103_b0080","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1586\/14760584.7.2.209","article-title":"Current challenges in the development of vaccines for pneumonic plague","volume":"7","author":"Smiley","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"29\u201330","key":"10.1016\/j.vaccine.2019.07.103_b0085","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1016\/j.vaccine.2011.04.084","article-title":"Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague","volume":"29","author":"Williamson","year":"2011","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2019.07.103_b0090","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.4049\/jimmunol.163.12.6448","article-title":"Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling","volume":"163","author":"Brewer","year":"1999","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2019.07.103_b0095","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/sji.12042","article-title":"Multiple antigen peptide containing B and T cell epitopes of F1 antigen of Yersinia pestis showed enhanced Th1 immune response in murine model","volume":"77","author":"Ali","year":"2013","journal-title":"Scand J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.07.103_b0100","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.intimp.2011.10.012","article-title":"Evaluation of CD4+\/CD8+ T-cell expression and IFN-\u03b3, perforin secretion for B-T constructs of F1 and V antigens of Yersinia pestis","volume":"12","author":"Gupta","year":"2012","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"10.1016\/j.vaccine.2019.07.103_b0105","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-3083.2009.02365.x","article-title":"Cell-mediated immune response and Th\/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis","volume":"71","author":"Gupta","year":"2010","journal-title":"Scand J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2019.07.103_b0110","doi-asserted-by":"crossref","first-page":"897","DOI":"10.4049\/jimmunol.1100174","article-title":"Yersinia pestis YopE contains a dominant CD8 T cell epitope that confers protection in a mouse model of pneumonic plague","volume":"187","author":"Lin","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.07.103_b0115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.micpath.2015.07.012","article-title":"MAP of F1 and V antigens from Yersinia pestis astride innate and adaptive immune response","volume":"87","author":"Rai","year":"2015","journal-title":"Microb Pathog"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2019.07.103_b0120","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cellimm.2012.07.002","article-title":"Cell-mediated immune response to epitopic MAP (multiple antigen peptide) construct of LcrV antigen of Yersinia pestis in murine model","volume":"278","author":"Shreewastav","year":"2012","journal-title":"Cell Immunol"},{"issue":"39","key":"10.1016\/j.vaccine.2019.07.103_b0125","doi-asserted-by":"crossref","first-page":"6802","DOI":"10.1016\/j.vaccine.2010.12.062","article-title":"Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge","volume":"29","author":"Wang","year":"2011","journal-title":"Vaccine"},{"issue":"44","key":"10.1016\/j.vaccine.2019.07.103_b0130","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1016\/j.vaccine.2017.05.092","article-title":"Novel CTL epitopes identified through a Y. pestis proteome-wide analysis in the search for vaccine candidates against plague","volume":"35","author":"Zvi","year":"2017","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2019.07.103_b0135","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1128\/iai.61.1.23-31.1993","article-title":"Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha","volume":"61","author":"Nakajima","year":"1993","journal-title":"Infect Immun"},{"issue":"52","key":"10.1016\/j.vaccine.2019.07.103_b0140","doi-asserted-by":"crossref","first-page":"6901","DOI":"10.1016\/j.vaccine.2008.09.063","article-title":"Antibodies and cytokines independently protect against pneumonic plague","volume":"26","author":"Kummer","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2019.07.103_b0145","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.vaccine.2009.09.127","article-title":"A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity","volume":"28","author":"Schabowsky","year":"2009","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2019.07.103_b0150","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1158\/0008-5472.CAN-09-4480","article-title":"4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines","volume":"70","author":"Sharma","year":"2010","journal-title":"Cancer Res"},{"issue":"39","key":"10.1016\/j.vaccine.2019.07.103_b0155","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.1016\/j.vaccine.2014.07.015","article-title":"Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant","volume":"32","author":"Dinc","year":"2014","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2019.07.103_b0160","doi-asserted-by":"crossref","first-page":"7295","DOI":"10.4049\/jimmunol.179.11.7295","article-title":"Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling","volume":"179","author":"Elpek","year":"2007","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2019.07.103_b0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047123","article-title":"Development of bioluminescent bioreporters for in vitro and in vivo tracking of Yersinia pestis","volume":"7","author":"Sun","year":"2012","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.vaccine.2019.07.103_b0170","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0264-410X(96)00303-9","article-title":"A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague","volume":"15","author":"Williamson","year":"1997","journal-title":"Vaccine"},{"issue":"11\u201312","key":"10.1016\/j.vaccine.2019.07.103_b0175","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0264-410X(98)80110-2","article-title":"Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine","volume":"16","author":"Heath","year":"1998","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2019.07.103_b0180","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1574-695X.1999.tb01229.x","article-title":"The SCID\/Beige mouse as a model to investigate protection against Yersinia pestis","volume":"23","author":"Green","year":"1999","journal-title":"FEMS Immunol. Med. Microbiol"},{"issue":"4\u20135","key":"10.1016\/j.vaccine.2019.07.103_b0185","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0264-410X(00)00159-6","article-title":"A single dose sub-unit vaccine protects against pneumonic plague","volume":"19","author":"Williamson","year":"2000","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2019.07.103_b0190","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1128\/CVI.00398-06","article-title":"Development of in vitro correlate assays of immunity to infection with Yersinia pestis","volume":"14","author":"Bashaw","year":"2007","journal-title":"Clin. Vaccine Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2019.07.103_b0195","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1128\/IAI.73.6.3598-3608.2005","article-title":"Human immune response to a plague vaccine comprising recombinant F1 and V antigens","volume":"73","author":"Williamson","year":"2005","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2019.07.103_b0200","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.micpath.2006.09.003","article-title":"Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates","volume":"42","author":"Williamson","year":"2007","journal-title":"Microb Pathog"},{"issue":"2","key":"10.1016\/j.vaccine.2019.07.103_b0205","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.vaccine.2010.08.099","article-title":"TNF\u03b1 and IFN\u03b3 contribute to F1\/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague","volume":"29","author":"Lin","year":"2010","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2019.07.103_b0210","doi-asserted-by":"crossref","first-page":"7304","DOI":"10.1128\/IAI.73.11.7304-7310.2005","article-title":"Cell-mediated protection against pulmonary Yersinia pestis infection","volume":"73","author":"Parent","year":"2005","journal-title":"Infect. Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2019.07.103_b0215","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/eji.200324278","article-title":"Expression and function of 4-1BB during CD4 versus CD8 T cell responses in vivo","volume":"34","author":"Dawicki","year":"2004","journal-title":"Eur. J Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2019.07.103_b0220","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1084\/jem.190.10.1535","article-title":"Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy","volume":"190","author":"Mittler","year":"1999","journal-title":"J Exp. Med"},{"issue":"7264","key":"10.1016\/j.vaccine.2019.07.103_b0225","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nature08402","article-title":"Membrane-bound Fas ligand only is essential for Fas-induced apoptosis","volume":"461","author":"O' Reilly","year":"2009","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.vaccine.2019.07.103_b0230","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1172\/JCI32426","article-title":"Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent","volume":"117","author":"Zhang","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2019.07.103_b0235","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/731604","article-title":"Advanced development of the rF1V and rBV A\/B vaccines: progress and challenges","volume":"2012","author":"Hart","year":"2012","journal-title":"Adv. Prev. Med"},{"issue":"9","key":"10.1016\/j.vaccine.2019.07.103_b0240","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1080\/21645515.2016.1175261","article-title":"Immunogenicity and safety of subunit plague vaccine: A randomized phase 2a clinical trial","volume":"12","author":"Chu","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.vaccine.2019.07.103_b0245","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/1091581813497405","article-title":"Preclinical safety assessment of a recombinant plague vaccine (rF1V)","volume":"32","author":"Price","year":"2013","journal-title":"Int J Toxicol"},{"issue":"6","key":"10.1016\/j.vaccine.2019.07.103_b0250","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1128\/IAI.00185-06","article-title":"Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection","volume":"74","author":"Parent","year":"2006","journal-title":"Infect. Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2019.07.103_b0255","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.4049\/jimmunol.1003303","article-title":"IL-17 contributes to cell-mediated defense against pulmonary Yersinia pestis infection","volume":"186","author":"Lin","year":"2011","journal-title":"J. Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2019.07.103_b0260","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1586\/14760584.2014.880340","article-title":"SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines","volume":"13","author":"Sharma","year":"2014","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2019.07.103_b0265","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nri2526","article-title":"The role of TNF superfamily members in T-cell function and diseases","volume":"9","author":"Croft","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2019.07.103_b0270","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1158\/0008-5472.CAN-08-3141","article-title":"Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel from of 4-1BBL eradicates established tumors","volume":"69","author":"Sharma","year":"2009","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.vaccine.2019.07.103_b0275","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1158\/0008-5472.CAN-14-1768-A","article-title":"SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines","volume":"74","author":"Srivastava","year":"2014","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.vaccine.2019.07.103_b0280","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1128\/IAI.01529-06","article-title":"Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection","volume":"75","author":"Philipovskiy","year":"2007","journal-title":"Infect Immun"},{"issue":"16","key":"10.1016\/j.vaccine.2019.07.103_b0285","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1016\/j.vaccine.2009.02.016","article-title":"CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague","volume":"27","author":"Amemiya","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2019.07.103_b0290","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2249.1999.00859.x","article-title":"An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model","volume":"116","author":"Williamson","year":"1999","journal-title":"Clin Exp Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19310242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19310242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:34:05Z","timestamp":1759401245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19310242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":58,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0264410X19310242"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.103","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.103","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}